When a Toronto-headquartered investment firm acquires a Delaware biolife sciences company, Cyprus merger control is not the obvious pressure point. Yet the notification filed on 19 March 2025 under Article 10 of the Law on Control of Business Concentrations No. 83(I)/2014 placed the transaction squarely within the jurisdiction of the Επιτροπή Προστασίας του Ανταγωνισμού (ΕΠΑ). Decision 19/2025, file reference 08.05.001.025.014, approved the deal unanimously — but the path to that approval repays careful reading for any practitioner advising on cross-border M&A with a Cyprus nexus.
The Parties
The acquirers named in the notification are Archimedes Blocker, Inc. and Archimedes Splitter, LP, collectively referred to in the decision as the "Archimedes" entities or the "Purchasers." Decision 19/2025, ΕΠΑ, para. 1. Their ultimate beneficial owner is Brookfield Corporation, an international investment firm headquartered in Toronto, Canada. Decision 19/2025, ΕΠΑ, para. 3.
The Commission's description of Brookfield's activities is worth noting precisely: the firm deploys concentrated capital globally across asset management, renewable energy transition, infrastructure, private equity, and real estate. Decision 19/2025, ΕΠΑ, para. 3. The notification also disclosed that Brookfield holds joint control over Brookfield Oaktree Holdings, LLC — formerly Oaktree Capital Group, LLC — and over Castlelake, L.P. Oaktree focuses on corporate credit, private equity, real estate assets, and listed securities. Castlelake is an alternative asset manager specialising in asset-based investments across private special finance, real assets, and aviation markets. Both entities were therefore included in the Commission's turnover analysis.
The target is CPI Holdco, LLC, a company incorporated under the laws of the State of Delaware, operating under the trade name Antylia Scientific. Decision 19/2025, ΕΠΑ, para. 3. Antylia Scientific is a manufacturer and provider of biolife sciences and environmental testing tools, organised across three business segments: Diagnostic Products, Environmental Products, and Core Products. Decision 19/2025, ΕΠΑ, para. 20.
Notification Procedure
The notification reached the Commission on 19 March 2025. This filing date is not administrative background: under Article 10 of the Law, the notification triggers the Commission's jurisdiction and starts the procedural clock. Decision 19/2025, ΕΠΑ, para. 1.
Two procedural steps followed promptly. On 21 March 2025, the Minister of Energy, Commerce and Industry was notified by letter in accordance with Article 16 of the Law. Decision 19/2025, ΕΠΑ, para. 4. On 28 March 2025, the notification was published in the Official Gazette of the Republic of Cyprus, as Article 10 of the Law requires. Decision 19/2025, ΕΠΑ, para. 5.
The Commission's Service (Υπηρεσία) completed its preliminary assessment under Article 17 of the Law and submitted a written report to the Commission on 11 April 2025, setting out its reasoned opinion on the compatibility of the concentration with competition in the market. Decision 19/2025, ΕΠΑ, para. 6. The Commission issued its decision on 16 April 2025 — less than four weeks from the notification date.
Market Definition: Three Cyprus Product Markets
The Commission grounded its market definition exercise in Annex I of the Law, which sets out the criteria for defining relevant product/service markets and relevant geographic markets. Decision 19/2025, ΕΠΑ, para. 18. It examined each of Antylia Scientific's three business segments as they operated in Cyprus.
Analytical Reference Materials (ARM). In Cyprus, Antylia Scientific sells only analytical reference materials (ARM) within its Diagnostic Products segment — not the broader range of microbiological tests and infectious disease panels it offers globally. Decision 19/2025, ΕΠΑ, para. 23. The Commission drew on its own prior decision on the sale of diagnostic products and defined the first relevant product market as the sale of analytical reference materials (ARM). Decision 19/2025, ΕΠΑ, paras. 25–26.
Environmental Diagnostic Consumables. For Environmental Products, Antylia manufactures and supplies consumables used in sampling, preparation, and analysis in environmental applications. Decision 19/2025, ΕΠΑ, para. 27. The parties acknowledged no prior decisions by the Commission or the European Commission specifically addressing this product category. Decision 19/2025, ΕΠΑ, para. 28. The Commission accepted the parties' position that all environmental testing tools share the same general function — testing for a contaminant — and defined the second relevant product market as the sale of environmental diagnostic consumables. Decision 19/2025, ΕΠΑ, paras. 29–30.
Laboratory Temperature Management Equipment and Consumables. Core Products cover laboratory equipment and consumables primarily for temperature management and sample preparation workflows, as well as general laboratory consumables and equipment. Decision 19/2025, ΕΠΑ, para. 31. The Commission noted the European Commission's approach in COMP/M.6175 Danaher/Beckman Coulter and COMP/M.5611 Agilent/Varian, which identified up to nine technical sub-segments within analytical instruments. Decision 19/2025, ΕΠΑ, para. 32. It also cited its own Decision 81/2021 (KKR & Co. Inc. / Dr. Urs Spitz / Biosynth Beteiligungs AG) on the market for laboratory and bioscience products. Decision 19/2025, ΕΠΑ, para. 33. The third relevant product market was defined as the sale of laboratory temperature management equipment and consumables. Decision 19/2025, ΕΠΑ, para. 34.
On geographic scope, the Commission applied a single standard across all three markets: the territory of the Republic of Cyprus. Decision 19/2025, ΕΠΑ, para. 36.
Competitive Analysis: No Affected Market
With the relevant markets defined, the Commission turned to compatibility assessment under Articles 20 and 21 of the Law — asking whether the concentration would significantly impede competition in the Republic or a substantial part of it, particularly by creating or strengthening a dominant position. Article 19 criteria informed the analysis. Decision 19/2025, ΕΠΑ, para. 17.
The analysis was short because the facts were clear.
On horizontal overlap: only Antylia Scientific operates in the three defined Cyprus markets. Brookfield — including its portfolio companies under joint control, Oaktree and Castlelake — does not operate in any of these markets in Cyprus. Decision 19/2025, ΕΠΑ, para. 37. The Commission therefore found no horizontal overlap and, by extension, no affected market arising from horizontal activity. Decision 19/2025, ΕΠΑ, para. 38.
On vertical relationships: neither party operates at an upstream or downstream level of the relevant markets in Cyprus. Decision 19/2025, ΕΠΑ, para. 39. The Commission concluded that no affected market arises from a vertical relationship or any other relationship between the parties' activities. Decision 19/2025, ΕΠΑ, para. 40.
The combined finding: no affected market from horizontal or vertical overlap, and no other markets in which the notified concentration could have significant effects. No further compatibility assessment was therefore required. Decision 19/2025, ΕΠΑ, para. 41.
The Approval
Acting under Article 22 of the Law, the Commission "ομόφωνα αποφάσισε να μην αντιταχθεί" — unanimously decided not to oppose the notified concentration — and declared it compatible with the functioning of competition in the market. Decision 19/2025, ΕΠΑ, para. 43.
The Panel comprised President Eva Pantzari and Members Aristos Aristeidou Palouzas, Neofytos Mauronikola, and Ioanna Sapidou. Decision 19/2025, ΕΠΑ, header.
"Not opposing" under Article 22 is the operative form of Phase I clearance in Cyprus merger control. It does not imply conditional approval or ongoing monitoring obligations in the absence of commitments — conditions that were not raised or required here.
Practitioner Takeaways
Notification threshold and obligation. The concentration qualified as a "concentration of major importance" under Article 3(2)(α) of the Law. The global turnover of Brookfield (including jointly controlled entities Oaktree and Castlelake) and the Cyprus-specific turnover of the target both featured in the threshold analysis, even though the target's Cyprus revenues were commercially modest. Decision 19/2025, ΕΠΑ, paras. 14–16. Practitioners should identify all entities in the acquirer's group subject to consolidation or joint control when testing notification thresholds.
Scope of the notification. The notification must identify all entities within the ultimate beneficial owner's group that are active in Cyprus, including joint-venture vehicles. Brookfield's disclosure of its joint control positions over Oaktree and Castlelake shaped the Commission's horizontal and vertical analysis — and the clean result depended on the accuracy of that disclosure.
Three-segment targets need three market analyses. Where a target operates across multiple product lines, each Cyprus-active segment requires its own market definition. The Commission did not collapse Antylia's three segments into a single market — it worked through each in sequence, drawing on EU precedent and its own prior decisions where available.
Redacted turnover figures. Commercially sensitive turnover data in Decision 19/2025 is redacted and indicated by {.}. The public version of the decision nonetheless contains the full legal analysis and all operative paragraphs. Every answer carries its citation; practitioners can rely on the public text for the Commission's reasoning.
Timeline. Filing on 19 March, Gazette publication on 28 March, service submission on 11 April, decision on 16 April. Where the notification package is complete and no affected markets arise, the Commission's Phase I process can run to conclusion quickly. Build this into transaction timelines where Cyprus clearance is a condition precedent.
Frequently Asked Questions
Q: Does every cross-border acquisition involving a Cyprus-registered or Cyprus-active entity require notification to the ΕΠΑ?
A: Not automatically. Notification under Article 10 of Law 83(I)/2014 is required only where the concentration meets the "major importance" thresholds set out in Article 3(2) of the Law. Those thresholds examine combined worldwide turnover and Cyprus-specific turnover across all entities within the group. The Brookfield/Antylia file confirms that the group's global footprint — including jointly controlled entities — is aggregated for threshold purposes, even where the target's Cyprus revenues are relatively small.
Q: What is an "affected market" and why does it matter?
A: An affected market is defined in Annex I of Law 83(I)/2014. It arises where the parties' activities overlap horizontally in the same product and geographic market above a defined share threshold, or where a vertical supply relationship exists between upstream and downstream markets. Where no affected market exists, the Commission is not required to conduct a full competitive effects analysis under Articles 20 and 21, and clearance at Phase I is the standard outcome, as in Decision 19/2025.
Q: How long does Cyprus Phase I merger review take?
A: The Law sets statutory timeframes, but Decision 19/2025 illustrates a 28-day cradle-to-decision period: notification on 19 March 2025, ministerial notification on 21 March, Gazette publication on 28 March, service report on 11 April, and decision on 16 April. Clean files with no affected markets and complete notification packages can move quickly. Practitioners should nonetheless account for the Commission's statutory review period and not assume every transaction will replicate this pace.
Q: What role does EU competition precedent play in the ΕΠΑ's market definition?
A: The Commission draws on European Commission decisions as guidance, particularly where no prior Cyprus precedent exists. In Decision 19/2025, the Commission cited COMP/M.6175 Danaher/Beckman Coulter and COMP/M.5611 Agilent/Varian when addressing the laboratory instruments segment, and its own Decision 81/2021 (KKR/Biosynth) for laboratory and bioscience products. EU precedent does not bind the ΕΠΑ, but it shapes the Commission's analytical framework — and practitioners should reference relevant EU decisions in their notification submissions. Primary sources, not summaries.
OmniLaw.ai gives practitioners direct access to the full text of ΕΠΑ decisions, including the original Greek text of Decision 19/2025, alongside structured analysis of Cyprus merger control filings. Search by case number, sector, or outcome at omnilaw.ai.
